走进园区，首批入驻企业已进入设备安装阶段。"入驻园区有助于我们进一步扩大生产场地，为业 务持续增长提供产能保障。"作为首批入园企业之一，海口瓷都忠诚义齿制造有限公司董事长陈富告诉 海南日报全媒体记者，从前期对接到收房入驻，园区的厂房品质及专业运营服务让他们对未来发展充满 信心。目前，落地企业类型覆盖数字医疗、高端耗材、第三方检测等细分领域，初步形成产业集群效 应。 除生物医药主阵地外，东湖高新集团在海南的第二个产业平台——"东湖高新海口数智科技创新平 台"近日正式签约。该平台占地68亩，建筑面积约6万平方米，将聚焦数字经济、智能制造、信息技术等 领域，与海口生物城形成"双轮驱动"，助力海口培育新质生产力。 自贸港首个"省际飞地"标志性项目落地企业超30家 加快打造生物医药产业集群 海南日报讯(海南日报全媒体记者 郭萃)近日，在海口国家高新区美安生态科技新城内，东湖高新 海口生物城项目现场一派繁忙景象，标准化厂房鳞次栉比，入驻企业正紧锣密鼓开展设备调试，首批投 产企业预计今年上半年实现完工投产。作为海南自贸港首个"省际飞地"标志性项目，该园区已吸引超过 30家企业签约落地，注册在园企业达130余家，涵盖生物医药 ...

Core Viewpoint - Spectral Medical Inc. has secured a non-dilutive financing agreement with Vantive US Healthcare LLC for up to US$10 million to support the commercialization of its blood filtration therapy, Toraymyxin™ (PMX) [2][4][5]. Financing Details - The financing consists of a senior secured promissory note with a total principal amount of up to US$10 million, which can be drawn in up to four tranches [2][3]. - The first tranche of US$4 million was triggered on May 6, 2025, upon the execution of the agreement [4]. - The remaining tranches are contingent upon specific milestones outlined in the agreement [4]. Company Strategy and Milestones - The funds will support Spectral's evidence generation strategy and the path to commercialization of PMX, which is designed to remove endotoxin from the bloodstream in patients with sepsis [3][4]. - The company does not anticipate needing additional funding to meet key upcoming milestones, including the release of topline results and U.S. FDA submission [4]. Management Commentary - The CEO of Spectral expressed gratitude for the partnership with Vantive, emphasizing the non-dilutive nature of the funding and the alignment between the two companies [5]. Product Overview - PMX is a therapeutic hemoperfusion device that has been approved for use in Japan and Europe and has been utilized over 360,000 times [11]. - The device is currently seeking U.S. FDA approval and has received Breakthrough Device Designation for the treatment of endotoxic septic shock [11]. Clinical Trial Information - The Tigris Trial is a confirmatory study comparing PMX in addition to standard care versus standard care alone, designed as a 2:1 randomized trial involving 150 patients [12].

Group 1 - Multiple regions in China, including Zhejiang, Henan, Yunnan, Jiangsu, and Hubei, have announced the establishment or completion of registration for mother funds focusing on sectors such as artificial intelligence, integrated circuits, semiconductors, new materials, high-end equipment, optoelectronic information, new energy, biomedicine, and medical devices [1][2] - Wuhan has announced a plan to create a 300 billion yuan mother-son fund cluster, with a maximum allowable loss of 100% [2][30] - The Hangzhou Science and Technology Innovation Fund is seeking general partners to establish sub-funds aimed at supporting strategic emerging industries in the city [3][4] Group 2 - The Zhengzhou Aviation Port Emerging Industry Development Equity Investment Fund has officially launched its sub-fund management institution recruitment, with a total scale of 10 billion yuan [5][6] - The Zhejiang provincial government is preparing a 10 billion yuan future industry fund and a 10 billion yuan merger mother fund [6][7] - The Yunnan Province High-Quality Agricultural Equity Investment Fund is seeking sub-fund management institutions to invest in key agricultural sectors [7][8] Group 3 - The Luoyang Angel Fund has completed registration with a total scale of 1 billion yuan, focusing on early-stage enterprises in sectors like artificial intelligence and new materials [9] - The Nantong Baoyuehu Science and Technology Innovation Mother Fund has been established with a total scale of 5 billion yuan, targeting strategic emerging industries [10] - The Jiangsu Province has launched a 10 billion yuan AI industry fund to support the development of an AI ecosystem [29] Group 4 - The Chengdu High-tech Zone has established a fund cluster with a total scale exceeding 320 billion yuan, focusing on various industries including electronic information and healthcare [20][21] - The Long Triangle Digital Cultural Industry Fund has been signed with a total scale of 10 billion yuan, focusing on the digitalization of the cultural industry [22] - The Jilin Province Ginseng Industry Fund has been established with a scale of 1.2 billion yuan, focusing on the ginseng industry chain [27]

Group 1 - The core viewpoint emphasizes the innovation in financial products supporting technology-driven enterprises, highlighting the shift from traditional asset-backed loans to credit assessments based on talent and technology [1] - The case of Hangzhou Mailiu Technology, which secured 30 million RMB credit support through the "Talent Bank" model, illustrates the successful application of these innovative financial tools [1] - Recent policies from various regions aim to enhance financing channels for technology enterprises, including the establishment of a "Technology Board" in the bond market and improved access for private equity funds [1] Group 2 - The People's Bank of China is promoting pilot programs for financial technology innovations and encouraging the use of structural monetary policy tools to support private enterprises in technology and green sectors [2] - High-tech manufacturing investment in China showed a year-on-year growth of 8.8% from January to November 2024, indicating that technology innovation investment is crucial for industrial transformation and economic stability [2] - Experts suggest that enhancing capital market functions and broadening funding channels are essential for supporting technology innovation enterprises and facilitating their market entry [3] Group 3 - The current funding landscape emphasizes the "four investments" principle: early-stage, small-scale, long-term, and hard technology investments, which are vital for reshaping the national balance sheet [3] - Recommendations include improving the bond market's support for technology enterprises and prioritizing financing for national manufacturing champions and specialized small and medium enterprises [3]

Core Insights - Orchestra BioMed Holdings, Inc. is actively participating in multiple institutional investor conferences to discuss its innovative biomedical technologies and partnerships [1][2][3] Group 1: Upcoming Conferences - The company will participate in Chardan Capital's Trending Issues in Drug Development Conference on April 29, 2025, featuring a fireside chat with CEO David Hochman [1] - Management will also engage in a live fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, along with one-on-one meetings with investors [2] - Additionally, a live presentation is scheduled for the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, where management will host one-on-one meetings [3] Group 2: Company Overview - Orchestra BioMed focuses on accelerating high-impact biomedical technologies through risk-reward sharing partnerships with leading medical device companies [4] - The company's lead product candidate is atrioventricular interval modulation (AVIM) therapy for hypertension, a major global health risk [4] - Orchestra BioMed is also developing the Virtue Sirolimus AngioInfusion™ Balloon for atherosclerotic artery disease, which is a leading cause of mortality worldwide [4] - The company has strategic collaborations with Medtronic for AVIM therapy and with Terumo for the Virtue SAB [4]

Core Insights - The establishment of Qianhai Customs has significantly supported the high-level opening and high-quality development of foreign trade in Nanshan District, Shenzhen, with foreign trade value projected to exceed 890 billion yuan by 2024, up from approximately 400 billion yuan in 2019 [1] Group 1: Policy Support and Initiatives - Qianhai Customs has implemented a comprehensive policy toolkit covering 25 measures across 7 business areas, actively delivering policies to enterprises nearly 200 times [4] - The customs authority has collaborated with local government departments to hold nearly 50 special policy promotion meetings, reaching over 3,000 enterprises [4] - A platform for enterprises to go global has been established, integrating customs regulations into the "i Nanshan" government information platform for more convenient services [4] Group 2: Industry Development and Innovation - Nanshan District has become a hub for over 5,500 national high-tech enterprises, 310 specialized "little giant" companies, and 31 national manufacturing champions, with a high density of listed companies [2] - The district is witnessing a surge in emerging industries such as low-altitude economy, artificial intelligence, robotics, and biomedicine, with many advanced manufacturing enterprises leading China's manufacturing exports [2] Group 3: Trade Facilitation and Efficiency - Qianhai Customs has supported major projects like the Xili Lake International Science and Education City by providing tax research services and promoting a pilot reform of enterprise group processing trade supervision [5] - The customs authority has facilitated the internal transfer of production materials among six enterprise groups, with a total value of 130 million yuan in 2024 [5] - The customs has also reduced guarantee amounts by 260 million yuan and saved costs of 10.816 million yuan for enterprises through comprehensive external processing support [5] Group 4: International Trade and Compliance - As international trade grows, domestic enterprises face increasing risks related to legal compliance and market uncertainties abroad, prompting Qianhai Customs to actively address these challenges [7] - The customs has established a national-level research and evaluation base for technical trade measures in drones and medical devices in Nanshan District, participating in WTO/TBT meetings and collecting trade notifications [7] Group 5: AEO Certification and Impact - The number of AEO (Authorized Economic Operator) enterprises in Nanshan has increased from 45 in 2019 to 90, with their foreign trade value accounting for over 40% of the district's total by 2024 [8] - AEO enterprises in Nanshan experienced a nearly 30% year-on-year growth in foreign trade value in 2024, highlighting the importance of AEO certification in enhancing trade stability [8]

Core Viewpoint - The article discusses the trend of "Tech Returning to the City," highlighting how urban centers are integrating technology and innovation into their fabric, creating a new model for urban development and economic growth [3][6][10]. Group 1: Global Context - The concept of "Tech Returning to the City" was proposed in the EU's New Leipzig Charter in 2020, aiming to support small producers and tech startups to reintegrate into urban communities [3]. - International examples include New York's Silicon Alley, Kendall Square in Boston, and various tech hubs in Europe, which serve as models for urban renewal through technology [4][9]. Group 2: Domestic Developments - Major Chinese cities like Beijing, Shanghai, and Guangzhou are adopting similar plans to develop urban tech hubs, with specific initiatives outlined in their urban planning documents [9]. - Shenzhen is highlighted as a city where traditional urban centers like Luohu and Futian are evolving into tech-centric areas, reflecting a shift towards a knowledge economy [7][12]. Group 3: Shenzhen's Transformation - Luohu and Futian are exploring new growth avenues, with Luohu focusing on a modern industrial system and Futian developing a tech innovation zone [13][14]. - In 2024, Luohu signed over 60% of its projects in emerging fields like AI and health, while Futian's R&D investment grew by 38.33% to 1.36 billion yuan [13][14]. Group 4: Urban Space and Innovation - The article emphasizes the need for urban spaces to support innovation, highlighting the importance of physical and soft spaces for knowledge workers and enterprises [15][24]. - Shenzhen's urban landscape is evolving, with new business spaces and innovation parks being developed to accommodate tech industries and startups [16][20]. Group 5: Educational and Collaborative Ecosystems - Shenzhen's "Silicon Valley" in Nanshan is fostering collaboration between universities and tech companies, creating an open environment for knowledge sharing [18][19]. - Initiatives like the Shenzhen Innovation Academy are supporting young entrepreneurs, with significant funding and resources provided to startups [21][24]. Group 6: Future Directions - The article concludes that Shenzhen aims to build a "boundaryless city" that integrates education, technology, and industry, promoting a vibrant ecosystem for innovation [24][28]. - The emergence of incubators and innovation spaces in Shenzhen reflects a strategic approach to urban renewal, focusing on creating diverse and open environments for startups [28][29].

主办单位：中关村独角兽企业发展联盟、中关村联新生物医药产业联盟 媒体支持：思宇MedTech | 骨未来 | 眼未来 | 心未来 | MedRobot 承办单位： 北京集智未来人工智能产业创新基地有限公司 已邀请投资机构： （所有北京市国管、北京市区两级相关基金） 京国瑞基金管理公司、顺禧基金管理公司、北京高精尖基金、北京科创基金、中关村 资本、中关村科学城基金、星元资本、康桥资本、荷塘创投、首发展创投、启迪创投、中关村启航基金，等等。其他投资人也可以报名，请等待新通 知。 注：本期路演为 中关村论坛平行论坛"全球独角兽企业大会"的分论坛， 因此，对路演项目的阶段有所要求，请在提交报名后，等待我们联系。如果不 能参加本场，我们会安排到4月24日星期四。 希望参加路演的企业报名方式 点击文末 "阅读原文 "填写报名表，或者复制链接到浏览器中填写。 https://docs.qq.com/form/page/DUFBzS2xteFh1ZUph 或扫描二维码进行填写 北京中关村科学城创新发展有限公司 路演时间： 2025年3月31日星期一上午 路演形式：现场路演 地点：量子银座（北京市.近知春路地铁站） 联盟前身是 ...

Core Insights - Spectral Medical Inc. is advancing its Tigris trial, a Phase 3 study evaluating Polymyxin B Hemoperfusion (PMX) for treating endotoxemia and septic shock [2][4] - The company aims to finalize full enrollment of 150 evaluable patients by the end of March 2025, with 152 patients already enrolled [8] Enrollment Update - As of now, 152 patients have been enrolled in the Tigris trial, with six patients enrolled in February [8] - The trial is designed to randomize 150 patients in a 2:1 ratio, with 100 patients receiving PMX and 50 receiving standard care [6][8] - The company estimates that an additional four to seven patients are needed to reach the target of 150 evaluable patients [8] Product and Market Context - PMX is already approved for therapeutic use in Japan and Europe, having been safely used on over 340,000 patients [5] - Approximately 330,000 patients are diagnosed with septic shock annually in North America, highlighting the market potential for PMX [5]

高校，创新源头。 作者 I 刘博 陈晓 报道 I 投资界PEdaily 一群年轻面孔闯入创投圈。 投资界获悉，3D生成大模型公司影眸科技完成数千万美元 A 轮融资，由美团龙珠、字节 跳动领投，老股东红杉中国种子基金及奇绩创坛持续跟投。令人意外的是，公司团队平均 年龄只有2 4 岁。 这是一个孵化自上海科技大学的创业项目——2 0 2 0年，吴迪、张启煊、张龙文、曾初啸 等人创立影眸科技，团队与上科大共同提出的可控 3D 原生 DiT生成框架 CLAY 与 3D 服装生成框架 Dr e ssCod e，均获计算机图形学顶会 ACM SIGGRAPH 2 0 24 最佳论文提 名，被认为是新一代 3D 生成基础框架。 "现在我们经常跑上科大蹲项目。"此前一家知名早期投资机构的分享引起我们的注意。 不同于清华、上海交大、哈工大等传统名校，上科大乍听略显陌生，成立仅仅十余年，殊 不知已经累计孵化4 0多家科创企业。如此一幕，堪称中国科技成果转化大潮的一缕写 照。 团队平均24岁 刚刚，美团字节联手投了 影眸科技的故事，始于上科大的一间实验室。 出生于19 9 7年，吴迪在20 1 5年进入上科大学习，是该校招的第二届 ...